Expanded use of benzamidines in the Groebke-Blackburn-Bienaymé synthesis of imidazoles and their biological evaluation.

Kamryn Walker, Sydney Rivas, Erik Tillman-Smith, Kayla McLeod, Jeanee Bullock, Jacqueline Smith

Abstract readLetter

In one paragraph

Article in Beilstein journal of organic chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kamryn WalkerHoward University, Department of Chemistry, 525 College Street, Washington DC 10059, USA.ORCID https://orcid.org/0009-0002-5857-5774

Sydney RivasBowie State University, 14000 Jericho Park Dr, Bowie MD 20715, USA.

Erik Tillman-SmithBowie State University, 14000 Jericho Park Dr, Bowie MD 20715, USA.

Kayla McLeodBowie State University, 14000 Jericho Park Dr, Bowie MD 20715, USA.

Jeanee BullockHoward University, Department of Chemistry, 525 College Street, Washington DC 10059, USA.

Jacqueline SmithHoward University, Department of Chemistry, 525 College Street, Washington DC 10059, USA.ORCID https://orcid.org/0000-0003-2916-1273

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heterocyclic compounds are often considered privileged scaffolds because many bioactive molecules contain these moieties. Several inhibitors of the valosin-containing protein (VCP, also known as p97), a target for cancer therapeutics, contain 5 or 6-membered heterocyclic cores. With the rise of resistance among these VCP inhibitors, we propose a new class of heterocycles as potential cancer therapeutics. The Groebke-Blackburn-Bienaymé (GBB) reaction is a classic method to produce imidazole compounds. In our earlier study, we showed that acyclic amidines can effectively produce trisubstituted imidazoles known as benzyl imine tricyclic imidazoles (BITIs) via this multicomponent reaction. Herein, we report the first systematic evaluation of

Indexed as

acyclic amidinecancer therapeuticscytotoxicityGroebke–Blackburn–Bienaymé reactionimidazolesvalosin-containing protein

Identifiers

PMID42835876

DOI10.3762/bjoc.22.108

PMCPMC13635903

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.